UNI MEDICAL (02666) announces its performance for 2025, with a net profit attributable to ordinary equity holders of approximately 21.568 billion yuan, a year-on-year increase of 6.2%.

UNI MEDICAL (02666) announced its performance in 2025, with a revenue of approximately RMB 14.9395 billion, a year-on-year growth of 9.3%. The net profit attributable to ordinary equity holders of the company is approximately RMB 2.1568 billion, a year-on-year growth of 6.2%. The basic earnings per share is RMB 1.13, and it is proposed to distribute a dividend of HKD 0.36 per share in 2025, with a dividend payout ratio of 30%. In 2025, the comprehensive medical sector included a total of 65 medical institutions (including 5 Class III hospitals, 1 tertiary specialty hospital, and 30 secondary hospitals), with a total of 15,628 open beds. These institutions contributed RMB 8.183 billion in revenue, a year-on-year growth of 7.5%, and achieved a net profit of RMB 287.4 million, a year-on-year decrease of 39.3%. This decrease is mainly attributed to two factors: a decrease in average cost due to healthcare payment reform, and increased depreciation, amortization, and labor costs from the commissioning of new infrastructure projects. Apart from a year-on-year profit before tax growth of 3.9%, the steady improvement in operational efficiency in the medical health business through mergers and acquisitions and internal quality enhancement, as well as a significant reduction in funding costs in the financial business through optimization of financing structure, led to profit growth.